{"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"groups":[{"description":"Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)","id":"BG000","title":"Pazopanib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"50-59"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"60-69"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"70-79"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Eligible and treated patients"}